Home > Research > Influenza Antiviral and Hepatitis B Antiviral

Influenza Antiviral

Influenza drug development project

Hepatitis B Antiviral

Hepatitis B virus inhibitor project

  According to the World Health Organization, annual influenza outbreaks affect 300~500 million people and cause 25~50 million deaths worldwide every year. The annual epidemic outbreak is caused by antigenic drift, rendering ineffective of annual flu vaccine. Concern has also aroused by the continuous threat posed by newly emerging influenza viruses. The antivirals such as amantadine (Enzil®) and rimantadine (Flumadine®) have become resistant to influenza current circulating strains, such as 2009/H1N1 and H3N2; the neuraminidase inhibitor class of influenza drugs including oseltamivir (Tamiflu®) and zanamivir (Relenza®) are recommended to be administered within 48 hours of infection to be effective.

  Due to the defect of current antivirals against influenza and the threat of new influenza pandemics, TaiGen's new influenza antiviral development project is targeting a chosen site with the highest sequence conservation among all viruses. Compound possesses novel mechanism of action, cap-snatching, which inhibits virus replication and spread. It is effective against influenza type A and B as well as avian influenza (H7N9). The TaiGen’s anti-influenza compound is also effective given 72 hours after the onset of symptoms in the animal model study. It is expected to not only overcome neuraminidase inhibitor resistant viruses but also have pan-influenza protection properties.
  According to the data of World Health Organization, about 325 million people are carriers of chronic hepatitis B virus worldwide and nearly 800,000 people die from disease caused by hepatitis B virus each year. The hepatitis B vaccine is the major option for hepatitis B prevention, but it is ineffectiveness for reducing chronic hepatitis. China is the largest market of hepatitis B medication. In 2017, sales of nucleos(t)ide analogs reached a market size of RMB 8.3 billion (IMS).

  Novel mechanism of hepatitis B antiviral agent acts on eliminating hepatitis B virus DNA in infected liver cell. Nucleos(t)ide inhibitors are the primary choice of HBV treatment, but it cannot eliminate hepatitis B virus hidden in liver cell even if patients take medicine for long time. Other conventional medication such as interferon has poor effectiveness and significant side-effects. Thus, novel hepatitis B antiviral drug is urgently needed.